India Moves to Suspend Drug Manufacturing Licences Immediately Over Quality Failures
India is proposing a tougher regulatory regime that would allow authorities to suspend drug manufacturing licences immediately when quality failures are detected, a move aimed at preventing substandard medicines from remaining in circulation while manufacturers correct deficiencies. The proposal signals a sharper enforcement posture in one of the world’s largest pharmaceutical markets, where quality lapses can quickly become a public health and export credibility issue.
